Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis Source: Eur Respir Rev 2017; 26: 160004 Year: 2017
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011
The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Rates of change in FEV1 and D LCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients Source: Eur Respir J, 51 (4) 1702258; 10.1183/13993003.02258-2017 Year: 2018
5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
The combination of PDE4 and PDE5 inhibitors reduces YAP expression in IPF Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Treatment of lymphangioleiomyomatosis with anastrozole; a potent and selective non-steroidal aromatase inhibitor Source: Eur Respir J 2007; 30: Suppl. 51, 67s Year: 2007
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Preventive and therapeutic effects of phosphoinositide 3-kinase inhibitors on acute lung injury Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury Year: 2011
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020
Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence Source: Eur Respir J 2010; 36: 709-711 Year: 2010
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017